217 related articles for article (PubMed ID: 26055297)
1. Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries.
Karp CL; Lans D; Esparza J; Edson EB; Owen KE; Wilson CB; Heaton PM; Levine OS; Rao R
Vaccine; 2015 Jul; 33(30):3471-9. PubMed ID: 26055297
[TBL] [Abstract][Full Text] [Related]
2. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
3. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
[TBL] [Abstract][Full Text] [Related]
4. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
5. Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries.
Kristensen DD; Lorenson T; Bartholomew K; Villadiego S
Vaccine; 2016 Feb; 34(7):899-904. PubMed ID: 26778422
[TBL] [Abstract][Full Text] [Related]
6. Estimating the costs of the vaccine supply chain and service delivery for selected districts in Kenya and Tanzania.
Mvundura M; Lorenson K; Chweya A; Kigadye R; Bartholomew K; Makame M; Lennon TP; Mwangi S; Kirika L; Kamau P; Otieno A; Murunga P; Omurwa T; Dafrossa L; Kristensen D
Vaccine; 2015 May; 33(23):2697-703. PubMed ID: 25865467
[TBL] [Abstract][Full Text] [Related]
7. Improving cold chain systems: Challenges and solutions.
Ashok A; Brison M; LeTallec Y
Vaccine; 2017 Apr; 35(17):2217-2223. PubMed ID: 27670076
[TBL] [Abstract][Full Text] [Related]
8. What vaccine product attributes do immunization program stakeholders value? Results from interviews in six low- and middle-income countries.
Kristensen DD; Bartholomew K; Villadiego S; Lorenson K
Vaccine; 2016 Dec; 34(50):6236-6242. PubMed ID: 27836438
[TBL] [Abstract][Full Text] [Related]
9. Using solar-powered refrigeration for vaccine storage where other sources of reliable electricity are inadequate or costly.
McCarney S; Robertson J; Arnaud J; Lorenson K; Lloyd J
Vaccine; 2013 Dec; 31(51):6050-7. PubMed ID: 23933340
[TBL] [Abstract][Full Text] [Related]
10. Is freezing in the vaccine cold chain an ongoing issue? A literature review.
Hanson CM; George AM; Sawadogo A; Schreiber B
Vaccine; 2017 Apr; 35(17):2127-2133. PubMed ID: 28364920
[TBL] [Abstract][Full Text] [Related]
11. Outsourcing vaccine logistics to the private sector: The evidence and lessons learned from the Western Cape Province in South-Africa.
Lydon P; Raubenheimer T; Arnot-Krüger M; Zaffran M
Vaccine; 2015 Jun; 33(29):3429-34. PubMed ID: 25819709
[TBL] [Abstract][Full Text] [Related]
12. Annual World Vaccine Congress 2014: a re-evaluation of the value proposition for increasing vaccine thermostability.
Derwand R
Hum Vaccin Immunother; 2014; 10(10):3087-9. PubMed ID: 25483655
[TBL] [Abstract][Full Text] [Related]
13. The origins of the vaccine cold chain and a glimpse of the future.
Lloyd J; Cheyne J
Vaccine; 2017 Apr; 35(17):2115-2120. PubMed ID: 28364918
[TBL] [Abstract][Full Text] [Related]
14. Seizing market shaping opportunities for vaccine cold chain equipment.
Azimi T; Franzel L; Probst N
Vaccine; 2017 Apr; 35(17):2260-2264. PubMed ID: 28364940
[TBL] [Abstract][Full Text] [Related]
15. The impact of making vaccines thermostable in Niger's vaccine supply chain.
Lee BY; Cakouros BE; Assi TM; Connor DL; Welling J; Kone S; Djibo A; Wateska AR; Pierre L; Brown ST
Vaccine; 2012 Aug; 30(38):5637-43. PubMed ID: 22789507
[TBL] [Abstract][Full Text] [Related]
16. Desirable attributes of vaccines for deployment in low-resource settings.
Chen D; Zehrung D
J Pharm Sci; 2013 Jan; 102(1):29-33. PubMed ID: 23136115
[TBL] [Abstract][Full Text] [Related]
17. Using Data to Keep Vaccines Cold in Kenya: Remote Temperature Monitoring with Data Review Teams for Vaccine Management.
Lutukai M; Bunde EA; Hatch B; Mohamed Z; Yavari S; Some E; Chweya A; Kania C; Ross JC; Keddem C; Chandani Y
Glob Health Sci Pract; 2019 Dec; 7(4):585-597. PubMed ID: 31852740
[TBL] [Abstract][Full Text] [Related]
18. Vaccine process technology.
Josefsberg JO; Buckland B
Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
[TBL] [Abstract][Full Text] [Related]
19. Vaccine stabilization: research, commercialization, and potential impact.
Kristensen D; Chen D; Cummings R
Vaccine; 2011 Sep; 29(41):7122-4. PubMed ID: 21651941
[TBL] [Abstract][Full Text] [Related]
20. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
